TETI, ELISABETTA
 Distribuzione geografica
Continente #
NA - Nord America 6.907
AS - Asia 2.310
EU - Europa 1.595
SA - Sud America 333
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 11.203
Nazione #
US - Stati Uniti d'America 6.836
SG - Singapore 1.037
IT - Italia 476
CN - Cina 372
RU - Federazione Russa 271
BR - Brasile 265
HK - Hong Kong 223
VN - Vietnam 212
KR - Corea 194
DE - Germania 173
IE - Irlanda 135
GB - Regno Unito 91
JP - Giappone 79
FR - Francia 73
FI - Finlandia 63
IN - India 57
UA - Ucraina 56
SE - Svezia 55
NL - Olanda 54
CA - Canada 42
AT - Austria 32
PL - Polonia 28
AR - Argentina 26
MX - Messico 22
ES - Italia 21
IQ - Iraq 19
ZA - Sudafrica 18
BD - Bangladesh 17
ID - Indonesia 17
TR - Turchia 17
BE - Belgio 14
EC - Ecuador 12
CZ - Repubblica Ceca 10
PK - Pakistan 10
VE - Venezuela 10
GR - Grecia 9
CH - Svizzera 8
PH - Filippine 8
MA - Marocco 7
EG - Egitto 6
KG - Kirghizistan 6
UZ - Uzbekistan 6
CO - Colombia 5
IL - Israele 5
IR - Iran 5
LT - Lituania 5
PY - Paraguay 5
CL - Cile 4
KE - Kenya 4
LV - Lettonia 4
TN - Tunisia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
AU - Australia 3
BG - Bulgaria 3
JM - Giamaica 3
JO - Giordania 3
MY - Malesia 3
OM - Oman 3
PE - Perù 3
SA - Arabia Saudita 3
TW - Taiwan 3
AZ - Azerbaigian 2
DZ - Algeria 2
HN - Honduras 2
KH - Cambogia 2
KZ - Kazakistan 2
MK - Macedonia 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CG - Congo 1
CM - Camerun 1
DK - Danimarca 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
HR - Croazia 1
ML - Mali 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
SI - Slovenia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.203
Città #
Wilmington 1.670
Houston 1.062
Woodbridge 994
Singapore 597
Chandler 340
San Jose 292
Ashburn 227
Hong Kong 218
Fairfield 211
Rome 172
New York 138
Beijing 137
Ann Arbor 115
Dublin 109
Los Angeles 103
Council Bluffs 95
Ho Chi Minh City 82
Santa Clara 81
Seattle 81
Tokyo 76
The Dalles 74
Cambridge 73
Medford 67
Munich 55
Dearborn 52
Hanoi 49
Moscow 44
Buffalo 40
Orem 37
Dallas 36
Milan 35
Helsinki 33
Lawrence 31
Nuremberg 31
São Paulo 29
Lauterbourg 28
San Diego 28
London 27
Frankfurt am Main 22
Engelhard 21
North Bergen 19
Palo Alto 19
Montreal 18
Chicago 17
Toronto 17
Warsaw 17
Amsterdam 15
Jacksonville 15
Lappeenranta 15
Chennai 14
Denver 14
Brussels 13
Menlo Park 13
Stockholm 13
Vienna 13
Ciampino 12
Colorado Springs 12
Brooklyn 11
Manchester 11
Mumbai 11
Boardman 10
Guangzhou 10
Jakarta 10
Johannesburg 10
Shanghai 10
Zhengzhou 10
Boston 9
Haiphong 9
Mexico City 9
Phoenix 9
Redondo Beach 9
Seoul 9
Hefei 8
Rio de Janeiro 8
San Francisco 8
Da Nang 7
Lahore 7
Nanjing 7
Turku 7
Atlanta 6
Cedarhurst 6
Chandigarh 6
Elk Grove Village 6
Miami 6
Paris 6
Poplar 6
St. George 6
Athens 5
Baghdad 5
Belo Horizonte 5
Brno 5
Genzano di Roma 5
Istanbul 5
Manitou Springs 5
Najaf 5
Naples 5
Norwalk 5
Olomouc 5
Salvador 5
Tampa 5
Totale 8.180
Nome #
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 485
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 473
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 457
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 440
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 417
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 411
Abnormal cortical sources of resting state electroencephalographic rhythms in single treatment-naïve HIV individuals: A statistical z-score index 385
Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy: A qEEG study 362
Corrigendum to “Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy: A qEEG study” [Clin. Neurophysiol. 127 (2016) 3455–3469]((S1388245716305089)(10.1016/j.clinph.2016.09.001)) 355
Antiretroviral therapy affects the z-score index of deviant cortical EEG rhythms in naïve HIV individuals 351
Cerebral Multishell Diffusion Imaging Parameters are Associated with Blood Biomarkers of Disease Severity in HIV Infection 327
Corrigendum to “Abnormal cortical sources of resting state electroencephalographic rhythms in single treatment-naïve HIV individuals: A statistical z-score index” [Clin. Neurophysiol. 127 (2016) 1803–1812] (S138824571501559X) (10.1016/j.clinph.2015.12.007)) 304
Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis 302
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 296
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy 293
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report 279
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: A case report 249
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 230
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 172
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab 154
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 152
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 151
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 141
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers 137
Disruption of brain network organization in patients with human immunodeficiency virus (HIV) infection 136
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 135
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications 132
Multishell diffusion MRI reveals whole-brain white matter changes in HIV 130
Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in {SARS}-{CoV}-2 infected patients: a single center study 130
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 123
In patients with severe COVID-19, the profound decrease in the peripheral Bblood T-cell subsets is correlated with an increase of QuantiFERON-TB Gold Plus indeterminate rates and reflecting a reduced interferon-gamma production 111
Functional brain network reorganization in HIV infection 108
Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves 104
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients 101
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 100
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 100
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 93
Compartmental models for diffusion weighted MRI reveal widespread brain changes in HIV-infected patients 91
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 90
Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience 88
HUMAN ENDOGENOUS RETROVIRUSES EXPRESSION CORRELATES WITH HIV RESERVOIR, LYMPHOCYTES ACTIVATION AND LOW CD4 COUNT IN VIROLOGICALLY SUPPRESSED PATIENTS 87
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 87
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 87
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 86
HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA After Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort 85
HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication 84
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 83
The Impact of Viral and Bacterial Co-Infections and Home Antibiotic Treatment in SARS-CoV-2 Hospitalized Patients at the Policlinico Tor Vergata Hospital, Rome, Italy 79
Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study 77
The evolving landscape of COVID-19: Factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance 76
Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage. 75
null 74
Hepatitis B-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: viroimmunological and histological characterization 73
Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV. 68
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 68
A peculiar HBsAg isoforms composition characterizes chronic HDV coinfection respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 67
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 65
Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV mono-infection, that parallels HDV replicative and cytolytic activity. 61
Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine 61
Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection 60
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program 60
Total HIV DNA and cell-associated HIV RNA viral reservoirs in PBMCs and GALT in patients on triple-ART and switching to dual-ART regimens. 58
The transactivation of endogenous retroviruses correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients 56
HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch 56
Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Acinetobacter baumannii Infections 56
Chronic HDV coinfection is characterized by a peculiar HBsAg isoforms composition respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 54
Whole-brain white matter network reorganization in HIV 53
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 51
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 51
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 51
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 51
The transactivation of human endogenous retroviruses is associated with HIV-1 reservoir, lymphocyte activation and low CD4 count in virologically suppressed PLWH 49
Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers 36
Intrahepatic HDV Activity Is Fueled By Integrated HBV DNA-Derived HBs Independently From CccDNA Size 36
COVID ‐19 and Liver Injury, Beyond the First Pandemic Waves: Clinical and Immune‐Virological Features 34
Continuum of care nella popolazione tossicodipendente nell’ambito dell’infezione da HCV: dati di Real Life 33
COVID-19 and influenza vaccination among adults stably engaged in HIV care 27
Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide 19
HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential. 17
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 17
Malagnino Valutazione della risposta biochimica e virologica dopo 72 settimane di terapia con Bulevirtide ed analisi della cinetica virale intraepatica in una coorte di pazienti affetti da epatite delta. 17
A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity. 15
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 15
An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity 15
Chronic HDV coinfection is characterized by a more elevated production of all three HBsAg isoforms compared to HBV mono-infection, that parallels HDV replicative and cytolytic activity. 15
HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA 14
Intra-hepatic HDV replicative activity can be sustained by HBsAg production from HBV-DNA integration and can modulate virological response to bulevirtide 13
Totale 11.567
Categoria #
all - tutte 41.015
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.015


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 28 34 20
2021/2022522 39 31 33 38 2 64 29 52 68 42 24 100
2022/2023795 76 85 75 101 73 145 48 62 78 2 37 13
2023/2024437 50 9 44 29 28 97 15 14 5 76 7 63
2024/20251.737 75 245 179 103 37 123 203 143 166 170 156 137
2025/20263.356 376 152 333 342 340 142 490 419 476 286 0 0
Totale 11.567